PDUFA dates October 2024: FDA calendar and catalysts.
1 PDUFA date fell in October 2024: TLX101 (Oct 2024). The FDA calendar also recorded 60 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
PDUFA dates in October 2024
| PDUFA date | Company | Ticker | Drug | Indication | Source |
|---|---|---|---|---|---|
| Oct 2024 | Telix Pharmaceuticals Ltd | TLX | TLX101 | SEC Form 10-K, filed 2026-02-20 |
Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months
October 2024: other FDA decisions and filings
October 2024: dated readouts
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| Oct 2024Month disclosed | AMX0035 | AMLX | Topline readout | — | Positive | sec_424b |
| Oct 2024Month disclosed | ALTO-100 | ANRO | Topline readout | — | Negative | SEC Form 10-Q |
| Oct 2024Month disclosed | — | AQST | Topline readout | — | Met primary endpoint | SEC Form 10-Q |
| Oct 2024Month disclosed | ATH434 | ATHE | Interim readout | — | Positive | SEC 8-K Exhibit 99.1 |
| Oct 2024Month disclosed | — | GYRE | Topline readout | — | Met primary endpoint | SEC 8-K Exhibit 99.1 |
| Oct 2024Month disclosed | — | GYRE | Topline readout | — | Met primary endpoint | SEC 8-K Exhibit 99.1 |
| Oct 2024Month disclosed | — | JAZZ | Topline readout | — | Met primary endpoint | SEC Form 10-Q |
| Oct 2024Month disclosed | Tecentriq® (atezolizumab) | JAZZ | Topline readout | — | Met primary endpoint | SEC Form 10-Q |
| Oct 2024Month disclosed | Zepzelca (lurbinectedin) | JAZZ | Topline readout | — | Met primary endpoint | SEC Form 10-Q |
| Oct 2024Month disclosed | dabogratinib (TYRA-300) | TYRA | Interim readout | — | Positive | SEC Form 10-K |
| Oct 2024Month disclosed | — | VRCA | Interim readout | — | Positive | SEC 8-K Exhibit 99.1 |
| Oct 2024Month disclosed | — | ZLAB | Topline readout | — | Positive | SEC 8-K Exhibit 99.1 |
| October 7, 2024 | ISEMBYLD (apitegromab) | SRRK | Topline readout | non-ambulatory Type 2 and Type 3 SMA | Positive | sec_424b |
| October 22, 2024 | — | IMUX | Interim readout | — | Positive | sec_424b |
| October 22, 2024 | vidofludimus | IMUX | Interim readout | — | Positive | sec_424b |
| October 22, 2024 | — | IMUX | Interim readout | — | Positive | SEC Form 10-K |
| October 27, 2024 | JX07001 | LENZ | Topline readout | presbyopia in China | Positive | SEC Form 10-Q |
| October 29, 2024 | SPR720 | SPRO | Interim readout | NTM-PD not meeting its primary endpoint | Met primary endpoint | SEC Form 10-Q |
October 2024: trial starts and primary completions
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| Oct 2024Month disclosed | ZUSDURI (mitomycin) | URGN | Trial start | — | Completed | SEC Form 10-Q |
| Oct 2024Month disclosed | obefazimod (ABX464) | ABVX | Trial start | Crohn's disease | Completed | sec_424b |
| Oct 2024Month disclosed | CORE-008 | CGON | Trial start | — | Completed | SEC Form 10-Q |
| Oct 2024Month disclosed | VIRO-25 | GNLX | Trial start | recurrent NSCLC | Completed | SEC Form 10-Q |
| Oct 2024Month disclosed | RLYB212 | RLYB | Trial start | — | Completed | SEC 8-K Exhibit 99.1 |
| Oct 2024Month disclosed | Vancomycin Hydrochloride (vancomycin) | RXRX | Trial start | high-risk of CDI | Completed | SEC Form 10-K |
| October 6, 2024 | risvodetinib (IkT-148009) | IKT | Trial start | — | Completed | SEC Form 10-Q |
| October 29, 2024 | Joenja® (leniolisib) | PHAR | Trial start | — | Completed | SEC Form 8-K |
| Oct 2024Month disclosed | FHD-909 | FHTX | Trial start | — | Completed | SEC 8-K Exhibit 99.1 |
| Oct 2024Month disclosed | IDE275 | IDYA | Trial start | MSI-High tumors pursuant | Completed | SEC Form 10-K |
| Oct 2024Month disclosed | KT-621 | KYMR | Trial start | — | Completed | SEC 8-K Exhibit 99.1 |
| Oct 2024Month disclosed | ONUREG (azacitidine) | PMVP | Trial start | — | Completed | SEC Form 10-K |
| Oct 2024Month disclosed | sclerosis (AMT-162) | QURE | Trial start | — | Completed | SEC Form 10-K |
| October 29, 2024 | FSD-201 | QNTM | Trial start | — | Completed | SEC 8-K Exhibit 99.1 |
| Oct 2024Month disclosed | INT230 | INTS | Trial start | — | Completed | SEC 8-K Exhibit 99.1 |
Guided to a window that includes October 2024
Milestones the sponsor disclosed to a quarter, tightest windows first.
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| Q4 2024Quarter disclosed | — | ASND | Topline readout | — | Scheduled | SEC Form 8-K |
| Q4 2024Quarter disclosed | — | ASND | Topline readout | — | Scheduled | SEC 8-K Exhibit 99.1 |
| Q4 2024Quarter disclosed | firmonertinib (AST2818) | AVBP | Trial start | classical EGFR mutations | Scheduled | SEC 8-K Exhibit 99.1 |
| Q4 2024Quarter disclosed | AXS-07 | AXSM | Topline readout | — | Scheduled | SEC 8-K Exhibit 99.1 |
| Q4 2024Quarter disclosed | AUVELITY (dextromethorphan-bupropion) | AXSM | Topline readout | — | Scheduled | SEC 8-K Exhibit 99.1 |
| Q4 2024Quarter disclosed | reboxetine (AXS-12) | AXSM | Topline readout | — | Scheduled | SEC 8-K Exhibit 99.1 |
| Q4 2024Quarter disclosed | AXS-07 | AXSM | PDUFA date | — | Scheduled | SEC 8-K Exhibit 99.1 |
| Q4 2024Quarter disclosed | VYGLXIA (troriluzole) | BHVN | Interim readout | — | Scheduled | SEC 8-K Exhibit 99.1 |
| Q4 2024Quarter disclosed | BHV-1600 | BHVN | Trial start | — | Scheduled | SEC Form 10-Q |
| Q4 2024Quarter disclosed | TRAP (nephropathy) | BHVN | Trial start | — | Scheduled | SEC Form 10-Q |
| Q4 2024Quarter disclosed | VYGLXIA (troriluzole) | BHVN | Topline readout | — | Scheduled | SEC 8-K Exhibit 99.1 |
| Q4 2024Quarter disclosed | BHV-1310 | BHVN | Trial start | — | Scheduled | SEC Form 10-Q |
| Q4 2024Quarter disclosed | aglatimagene besadenovec (CAN-2409) | CADL | Topline readout | — | Scheduled | SEC 8-K Exhibit 99.1 |
| Q4 2024Quarter disclosed | GS-0321 | CGEN | Trial start | — | Scheduled | SEC 8-K Exhibit 99.1 |
| Q4 2024Quarter disclosed | — | FBIO | Topline readout | — | Scheduled | SEC Form 10-Q |
| Q4 2024Quarter disclosed | — | GALT | Topline readout | — | Scheduled | SEC Form 10-Q |
| Q4 2024Quarter disclosed | mebufotenin (GH001) | GHRS | Topline readout | — | Scheduled | SEC 8-K Exhibit 99.1 |
| Q4 2024Quarter disclosed | — | GOVX | Interim readout | — | Scheduled | SEC 8-K Exhibit 99.1 |
| Q4 2024Quarter disclosed | VYD2311 | IVVD | Interim readout | — | Scheduled | SEC 8-K Exhibit 99.1 |
| Q4 2024Quarter disclosed | — | NAMS | Topline readout | — | Scheduled | SEC 8-K Exhibit 99.1 |
4 more in October 2024 are on each drug page and in the calendar API (/api/v1/biotech/calendar?from=2024-10-01&to=2024-10-31).
25 more milestones are guided to a half-year or full-year window, or estimated from ClinicalTrials.gov primary completion dates, that overlaps October 2024. They are on each drug page and in the calendar API.
Questions
What PDUFA dates are in October 2024?
1 PDUFA date fell in October 2024: TLX101 (Oct 2024). The FDA calendar also recorded 60 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
Can these dates change?
Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.